.Maple Grove, Minnesota--(Newsfile Corp. - January 11, 2021) - StemoniX, a biotech company changing how new drugs are discovered, announced today their participation at the 2021 Biotech Showcase™ being held January 11-15th as part of OrganAi, a joint venture between StemoniX and Atomwise.
Maple Grove, Minnesota--(Newsfile Corp. - January 11, 2021) - StemoniX, a biotech company changing how new drugs are discovered, announced today their participation at the 2021 Biotech Showcase™ being held January 11-15th as part of OrganAi, a joint venture between StemoniX and Atomwise. The company will present recent advancements in Central Nervous System (CNS) disorders during an on-demand presentation that is available 24/7 before and during the meeting to registered attendees.
OrganAi has created a novel drug discovery engine by combining a human-first neural organoid platform from StemoniX with AtomNet® technology by Atomwise for accelerated small molecule drug discovery. The company uses human iPSC-derived complex 3D neural cultures with AI-based screening methods to successfully identify novel small molecule therapeutics for debilitating diseases. While initially focused on CNS and rare neurodevelopmental disorders, the approach is disease and target agnostic and can easily expand into other diseases and organ systems. Together these capabilities promise to rapidly identify and advance novel disease targets and compounds with potential for clinical translation to treat CNS disorders and beyond.
“We’re excited to start 2021 by attending the Biotech Showcase! It is the perfect place to promote the innovative venture between StemoniX and Atomwise - how together we will accelerate the progression of safer and more effective compounds through the drug discovery pipeline and ultimately identify additional partners to take these molecules into the clinic,” stated Ping Yeh, CEO and Co-founder of StemoniX.
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks.
“We are delighted that StemoniX will be representing OrganAi at the Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”
Interested parties are invited to contact Blake Anson (blake.anson@stemonix.com), Vice President of Business Development for additional information on the platforms and opportunities.
ABOUT BIOTECH SHOWCASE
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its 13th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.
ABOUT STEMONIX
StemoniX is empowering the discovery of new medicines through the convergence of novel human biology and software technologies. StemoniX develops and manufactures high-density, at-scale human induced pluripotent stem (iPSC) cell-derived neural and cardiac screening platforms for drug discovery and development. Predictive, accurate, and consistent, these human models enable scientists to quickly and economically conduct research with improved outcomes in a simplified workflow. Through collaborations with drug discovery organizations, StemoniX tests compounds in-house, creates new cell-based disease models, and operationalizes custom human iPSC disease models at large scale for high-throughput screening. With leading-edge iPSC technologies and data science, StemoniX is helping global institutions bring the most promising medicines to patients. To learn more about how StemoniX products and services are accelerating discoveries, please visit StemoniX.com.
ABOUT ATOMWISE
Atomwise is revolutionizing how drugs are discovered with AI. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets across 775 collaborations spanning more than 250 partners around the world. Our portfolio of joint ventures and partnerships with leading pharmaceutical, agrochemical, and emerging biotechnology companies represents a collective deal value approaching $7 billion. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. Learn more at atomwise.com or follow @AtomwiseInc.
Contacts
Ping Yeh
CEO StemoniX, Inc.
Email: ping.yeh@stemonix.com
Phone: (612) 807-9889
Andrew LaFrence
CFO StemoniX, Inc.
Email: andrew.lafrence@stemonix.com
Phone: (612) 802-9299
Sara Agee Le, PhD
VP of Marketing and Communications, Atomwise
Email: sagee@atomwise.com
Phone: (510) 590-6997
Follow Biotech Showcase at @EBDGroup and @Demy_Colton and tag your posts with #BiotechShowcase.
